GlycoEra
Pre-clinicalOur understanding of autoimmune disease has grown tremendously, and we now know specific circulating proteins drive many autoimmune diseases. However, existing therapies are broad acting with a narrow therapeutic index which limits them to being used as late-line treatments when the disease has become advanced. Using our best-in-class platform we can meet the moment and truly realize the promise of precision immunology by selectively degrading those offending proteins thus allowing for early ...
Private Company
Total funding raised: $40M
About
Our understanding of autoimmune disease has grown tremendously, and we now know specific circulating proteins drive many autoimmune diseases. However, existing therapies are broad acting with a narrow therapeutic index which limits them to being used as late-line treatments when the disease has become advanced. Using our best-in-class platform we can meet the moment and truly realize the promise of precision immunology by selectively degrading those offending proteins thus allowing for early ...